Literature DB >> 1759091

Prevalence and treatment of insomnia in the community: results from the Upper Bavarian Field Study.

S Weyerer1, H Dilling.   

Abstract

In the Upper Bavarian Field Study a total of 1,536 persons (15 yr of age and older) were interviewed by research psychiatrists. The prevalence of insomnia (last 7 days) identified with the aid of the Clinical Interview Schedule (CIS) was 28.5% (mild: 15.0%; moderate/severe: 13.5%). For both sexes sleep disorders increased with age. The female preponderance of insomnia was mainly associated with the middle and older age groups. In contrast to other psychiatric disorders, sleep disturbances were not associated with social class. Moderate/severe insomnia was strongly related to psychiatric diagnoses, the use of psychiatric in- and outpatient services and general hospitals. It also constituted a significant burden for the primary-care physicians, whereby the average annual consultation rate among mild (10.61) and moderate/severe insomniacs (12.87) was significantly higher compared to that for those without sleep disorders (5.25). A total of 33.7% of the insomniacs were treated with hypnotic and/or other psychotropic drugs during the week prior to the interview, whereby the drug consumption among moderate/severe insomniacs (48.5%) was significantly higher than that of mild insomniacs (20.4%).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1759091

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  36 in total

1.  A general model of the effects of sleep medications on the risk and cost of motor vehicle accidents and its application to France.

Authors:  J Menzin; K M Lang; P Levy; E Levy
Journal:  Pharmacoeconomics       Date:  2001-01       Impact factor: 4.981

2.  The Pittsburgh Sleep Quality Index in a multi-ethnic Asian population contains a three-factor structure.

Authors:  Hiromi W L Koh; Raymond Boon Tar Lim; Kee Seng Chia; Wei Yen Lim
Journal:  Sleep Breath       Date:  2015-02-04       Impact factor: 2.816

3.  Psychosocial correlates of insomnia in an adolescent population.

Authors:  Konstantinos E Siomos; Penelope-Alexia Avagianou; Georgios D Floros; Nikolaos Skenteris; Odysseas D Mouzas; Kyriaki Theodorou; Nikiforos V Angelopoulos
Journal:  Child Psychiatry Hum Dev       Date:  2010-06

4.  Moderators and mediators of the relationship between stress and insomnia: stressor chronicity, cognitive intrusion, and coping.

Authors:  Vivek Pillai; Thomas Roth; Heather M Mullins; Christopher L Drake
Journal:  Sleep       Date:  2014-07-01       Impact factor: 5.849

5.  Age and sleep disturbances among American men and women: data from the U.S. Behavioral Risk Factor Surveillance System.

Authors:  Michael A Grandner; Jennifer L Martin; Nirav P Patel; Nicholas J Jackson; Philip R Gehrman; Grace Pien; Michael L Perlis; Dawei Xie; Daohang Sha; Terri Weaver; Nalaka S Gooneratne
Journal:  Sleep       Date:  2012-03-01       Impact factor: 5.849

6.  Health-related quality of life in patients with insomnia treated with zopiclone.

Authors:  D Leger; M A Quera-Salva; P Philip
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

Review 7.  Residual effects of hypnotics: epidemiology and clinical implications.

Authors:  Annemiek Vermeeren
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

8.  Clinical and polysomnographic effects of trazodone CR in chronic insomnia associated with dysthymia.

Authors:  L Parrino; M C Spaggiari; M Boselli; G Di Giovanni; M G Terzano
Journal:  Psychopharmacology (Berl)       Date:  1994-12       Impact factor: 4.530

9.  Evaluation of trazodone and quetiapine for insomnia: an observational study in psychiatric inpatients.

Authors:  Shadi Doroudgar; Tony I-Fan Chou; Junhua Yu; Karen Trinh; Jai Pal; Paul J Perry
Journal:  Prim Care Companion CNS Disord       Date:  2013-11-07

10.  Prevalence and treatment of insomnia in general practice. A longitudinal study.

Authors:  F Hohagen; K Rink; C Käppler; E Schramm; D Riemann; S Weyerer; M Berger
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1993       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.